Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
公司代碼ETON
公司名稱Eton Pharmaceuticals Inc
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)
員工數量31
證券類型Ordinary Share
年結日Nov 09
公司地址21925 W Field Pkwy Ste 235
城市DEER PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編60010-7278
電話18477877361
網址https://etonpharma.com/
公司代碼ETON
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)